| First Author | Kelson CO | Year | 2024 |
| Journal | Cells | Volume | 13 |
| Issue | 19 | PubMed ID | 39404424 |
| Mgi Jnum | J:357520 | Mgi Id | MGI:7749087 |
| Doi | 10.3390/cells13191663 | Citation | Kelson CO, et al. (2024) Upregulation of Fatty Acid Synthase Increases Activity of beta-Catenin and Expression of NOTUM to Enhance Stem-like Properties of Colorectal Cancer Cells. Cells 13(19) |
| abstractText | Dysregulated fatty acid metabolism is an attractive therapeutic target for colorectal cancer (CRC). We previously reported that fatty acid synthase (FASN), a key enzyme of de novo synthesis, promotes the initiation and progression of CRC. However, the mechanisms of how upregulation of FASN promotes the initiation and progression of CRC are not completely understood. Here, using Apc/VillinCre and Apc(Min) mouse models, we show that upregulation of FASN is associated with an increase in activity of beta-catenin and expression of multiple stem cell markers, including Notum. Genetic and pharmacological downregulation of FASN in mouse adenoma organoids decreases the activation of beta-catenin and expression of Notum and significantly inhibits organoid formation and growth. Consistently, we demonstrate that NOTUM is highly expressed in human CRC and its expression positively correlates with the expression of FASN in tumor tissues. Utilizing overexpression and shRNA-mediated knockdown of FASN, we demonstrate that upregulation of FASN increases beta-catenin transcriptional activity, NOTUM expression and secretion, and enhances stem-like properties of human CRC cells. Pharmacological inhibition of NOTUM decreases adenoma organoids growth and proliferation of cancer cells. In summary, upregulation of FASN enhances beta-catenin signaling, increases NOTUM expression and stem-like properties of CRC cells, thus suggesting that targeting FASN upstream of the beta-catenin/NOTUM axis may be an effective preventative therapeutic strategy for CRC. |
